AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh
1. AstraZeneca plans to invest $50 billion in U.S. manufacturing by 2030. 2. New facility in Virginia will focus on weight management and metabolic drugs. 3. Investment aims to create tens of thousands of jobs and expand R&D. 4. CEO anticipates $80 billion annual revenue target, with half from the U.S. 5. Pharma tariffs and reshoring U.S. production influence the investment strategy.